The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.

Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.

The present invention is directed to methods and compositions for norovirus therapeutics, such as vaccines, and diagnostics.

Machine learning analysis for classifying agglutination of fluid samples. A method includes scanning a unique scannable code printed on a test card, wherein the test card comprises a negative control fluid sample, a positive control fluid sample, and a test fluid sample. The method includes capturing an image of the test card and providing the image of the test card to a machine learning algorithm configured to assess agglutination of the test fluid sample based on the image. The method includes receiving from the machine learning algorithm one or more of a qualitative analysis or a quantitative analysis of the agglutination of the test fluid sample.

A bioaerosol detector is operated in accordance with one or more first inputs. Operating the bioaerosol detector includes filtering pathogens from the air, extracting genetic material from the filtered pathogens, and analyzing the extracted genetic material to identify the filtered pathogens. While operating the bioaerosol detector in accordance with the one or more first inputs, a change is identified in an operating condition for the bioaerosol detector. In response, the bioaerosol detector is operated in accordance with one or more second inputs. At least one input of the one or more second inputs is distinct from a respective input of the one or more first inputs.

A bioaerosol detector is operated in accordance with one or more first inputs. Operating the bioaerosol detector includes filtering pathogens from the air, extracting genetic material from the filtered pathogens, and analyzing the extracted genetic material to identify the filtered pathogens. While operating the bioaerosol detector in accordance with the one or more first inputs, a change is identified in an operating condition for the bioaerosol detector. In response, the bioaerosol detector is operated in accordance with one or more second inputs. At least one input of the one or more second inputs is distinct from a respective input of the one or more first inputs.

An antibody that binds to a filovirus glycoprotein generally includes include a complementarity determining region (CDR) of any one of SEQ ID NO:27-36 or a combination of such CDRs. The antibody may be used in to detect filovirus in a biological sample obtained from a subject. The antibody also may be formulated into a pharmaceutical composition for administering to a subject having, or at risk of having, a filovirus infection.

The present disclosure is directed to antibodies binding to and neutralizing norovirus and methods for use thereof.

The disclosure relates to compositions, assays, methods and kits comprising one or more amino acid sequences of a filovirus protein, or a fragment thereof, which find use in the detection of a filovirus infection and/or the presence of antibodies specific for a filovirus in a biological sample.

Antibodies and antigen binding fragments that specifically bind to human metapneumovirus (hMPV) F protein and neutralize hMPV are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit an hMPV infection or detect a hMPV infection.